Novartis Pharma Schweiz AG Review

About Novartis Pharma Schweiz AG

Novartis Pharma Schweiz AG: A Global Healthcare Company Providing Innovative Solutions to Patients Worldwide

Novartis Pharma Schweiz AG is a leading global healthcare company based in Switzerland that provides innovative solutions to address the evolving needs of patients worldwide. The company has a strong presence in the pharmaceutical, biotechnology, and medical device industries, with a focus on research and development (R&D) to bring new treatments and therapies to market.

Founded in 1996 as a subsidiary of Novartis International AG, Novartis Pharma Schweiz AG has grown into one of the world's largest pharmaceutical companies. With operations in more than 140 countries around the world, Novartis is committed to improving patient outcomes through its innovative products and services.

The company's portfolio includes medicines for various therapeutic areas such as oncology, cardiology, respiratory diseases, neuroscience disorders, ophthalmology, dermatology and immunology. Some of its most well-known brands include Gilenya for multiple sclerosis treatment; Tasigna for chronic myeloid leukemia; Lucentis for age-related macular degeneration; Cosentyx for psoriasis treatment; Entresto for heart failure treatment; Zolgensma - gene therapy product used to treat spinal muscular atrophy (SMA); Kymriah - CAR-T cell therapy used to treat certain types of cancer.

In addition to its pharmaceuticals business unit which accounts for majority of its revenue generation , Novartis also operates two other business units: Sandoz (generics) and Alcon (eye care). Sandoz is one of the largest generic drug manufacturers globally while Alcon produces surgical equipment such as intraocular lenses used during cataract surgery.

Novartis' commitment towards innovation can be seen from their investment in R&D activities which accounted for approximately USD 9 billion or around 18% percent of net sales in 2020. The company has over 15 R&D centers across different geographies including Switzerland , US , UK , China among others . These centers are focused on developing new drugs using cutting-edge technologies like gene editing & cell therapies .

Apart from investing heavily into R&D activities , Novartis also focuses on sustainability initiatives . In fact it was ranked #1 by Corporate Knights Global Index among pharma companies globally . The company aims at reducing carbon footprint by sourcing renewable energy sources & reducing waste generation across all sites globally .

With an employee base exceeding over 100k people worldwide , diversity & inclusion are key pillars within organization culture . In fact it was ranked #2 by Refinitiv Diversity & Inclusion Index among pharma companies globally .

In conclusion,Novartis Pharma Schweiz AG is a global healthcare leader that continues to innovate with cutting-edge technologies while maintaining focus on sustainability initiatives. Its commitment towards improving patient outcomes through research-driven approach makes it stand out from other players within industry.